CovidVax show full list

Non-replicating viral vector Ad5

ImmunityBio + NantKwest
vaccine type: Non-replicating viral vector
Distribution updates
May 27NantKwest GMP manufacturing plant available to produce vaccine at scale (by
Human Testing updates (clinical trials)
Oct 15ImmunityBio has received authorization from U.S. FDA to begin phase 1 clinical trial of its vaccine (by
Animal Testing updates (pre-clinical trials)
start date: July 2020
Aug 03ImmunityBio announced positive preclinical results for its Ad5 vaccine against COVID-19 (by
early development updates
Aug 24ImmunityBio and NantKwest made an agreement to jointly develop and manufacture vaccines (by
Jun 01ImmunityBio's vaccine is one of 14 candidates being evaluated by Operation Warp Speed (by
Apr 14ImmunityBio and NantKwest are in active talks with FDA for vaccines to combat COVID-19 (by

contact | about | ©2020 project